| Everolimus for breast cancer and ibrutinib for mantle cell lymphoma are not cost-effective, NICE says Related items from OnMedica Study shows huge global variation in cancer drug costs MPs slam government for its poor management of Cancer Drugs Fund NHS cancer patients still denied treatments available in other countries Cancer Drugs Fund axes 25 treatments from list Put case for adding leukaemia drug to Cancer Drugs Fund, NICE tells company |
Thursday 18 August 2016
NICE set to remove two drugs from the Cancer Drugs Fund
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment